PROBLEM TO BE SOLVED: To provide a radiotherapy enhancing agent effective against radiation resistant cancer, and a therapeutic method of radiation resistant cancer using the radiotherapy enhancing agent.SOLUTION: A radiotherapy enhancing agent to radiation resistant cancer having an Arf6-AMAP1-PRKD2 pathway contains nucleic acid that inhibits expression of protein selected from the group consisting of Arf6, AMAP1, PRKD2, GEP100 and Rab5c, which is included in the Arf6-AMAP1-PRKD2 pathway, as an active ingredient. An radiotherapy enhancing agent to radiation resistant cancer having the Arf6-AMAP1-PRKD2 pathway wherein radiation resistant cancer further has a mevalonate pathway, and the enhancing agent contains a substance that inhibits an activity of enzyme included in the mevalonate pathway as an active ingredient. A radiotherapy method includes administering a radiotherapy enhancing agent, which contains nucleic acid that inhibits expression of protein selected from the group consisting of Arf6, AMAP1, PRKD2, GEP100 and Rab5c, which is included in the Arf6-AMAP1-PRKD2 pathway (or a substance that inhibits the activity of enzyme included in the mevalonate pathway), as an active ingredient, to a patient before and/or under radiotherapy to radiation resistant cancer having the Arf6-AMAP1-PRKD2 pathway (and mevalonate pathway).COPYRIGHT: (C)2015,JPO&INPIT【課題】放射線抵抗性癌に対して有効な放射線治療増強剤および前記放射線治療増強剤を用いる放射線抵抗性癌の治療方法を提供する。【解決手段】Arf6-AMAP1-PRKD2 経路を有する放射線抵抗性癌に対する放射線治療増強薬:Arf6-AMAP1-PRKD2経路に含まれる、Arf6、AMAP1、PRKD2、GEP100及びRab5cから成る群から選ばれるタンパク質の発現を阻害する核酸を有効成分として含有する。Arf6-AMAP1-PRKD2 経路を有する放射線抵抗性癌に対する放射線治療増強薬:放射線抵抗性癌がメバロン酸経路をさらに有し、メバロン酸経路に含まれる酵素の活性を阻害する物質を有効成分として含有する。Arf6-AMAP1-PRKD2 経路(及びメバロン酸経路)を有する放射線抵抗性癌に対する放射線治療前及び/又は治療中の患者に、Arf6-AMAP1-PRKD2経路に含まれる、Arf6、AMAP1、PRKD2、GEP100及びRab5cから成る群から選ばれるタンパク質の発現を阻害する核酸(またはメバロン酸経路に含まれる酵素の活性を阻害する物質)を有効成分として含有する放射線治療増強薬を投与することを含む、放射線治療方法。【選択図】なし
